Trump to unveil new drug pricing agreements with pharmaceutical firms

The White House intends to leverage these deals to provide state Medicaid programs with outpatient drug discounts mirroring international pricing models. In exchange for participation, companies would secure exemptions from mandatory Medicare discount pilot programs. While the administration frames this as a victory for healthcare affordability, the actual impact on patient out-of-pocket costs remains uncertain given that Medicaid already receives significant statutory discounts.

This initiative follows a pattern of pressure on the pharmaceutical sector. Since the revival of the "most favored nation" policy in May 2025, the administration has already inked deals with 17 manufacturers, including Pfizer, Eli Lilly, and Novo Nordisk. These policies have forced companies to shift commercial strategies, with many relocating manufacturing to the U.S. to mitigate tariff risks or pushing consumers toward the TrumpRx portal to maintain revenue volume. Industry group PhRMA continues to challenge the efficacy of these measures, arguing that pharmacy benefit managers remain the primary drivers of high costs, rather than manufacturer pricing structures.